The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Kenvue Inc. closed 13.19% below its 52-week high of $25.17, which the company achieved on May 8th.

Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Experts are raising concerns about Benadryl’s ability to cross the blood-brain barrier and potential lasting impacts ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

In a testament to its enduring strength and adaptive strategy, Johnson & Johnson (NYSE: JNJ) today announced a strong ...

The stock's fall snapped a four-day winning streak.

BAND-AID and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what some investors expect will be the groundwork for an eventual sale of the ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Its stock rose 2.9%, though it also said that market conditions remain sluggish. Shares of Kenvue rose 2.3% in shaky trading after the former division of Johnson & Johnson said CEO Thibaut Mongon is ...